Digest Network Come funziona
Network
/
Società
Io
Non verificato

Ionis Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

44 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/12/2025
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Industria
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/11/2025
Mercato del lavoro
Industria
Salute
Biotecnologia
Farmaceutica
Cardiologia
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Salute
Biotecnologia
Farmaceutica
Cardiologia
Finanza
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
12/11/2025
Eventi
Web e Social Network
Salute
Farmaceutica
Ionis to present at upcoming investor conferences
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/11/2025
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/11/2025
Web e Social Network
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Cardiologia
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/10/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Cardiologia
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Ionis reports third quarter 2025 financial results and highlights progress on key programs
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
27/10/2025
Web e Social Network
Eventi
Fiere
Industria
Scienza
Biotecnologia
Cardiologia
Salute
Farmaceutica
Sanità
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0